Trial Profile
A Phase 3, Open-Label, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2021
Price :
$35
*
At a glance
- Drugs Brincidofovir (Primary)
- Indications Adenovirus infections
- Focus Registrational; Therapeutic Use
- Acronyms AdVise
- Sponsors Chimerix
- 06 Jun 2018 Results assessing Brincidofovir in a subset of patients (solid organ transplant recipients and other HCTpatients; n=43) presented at the 2018 American Transplant Congress
- 22 Feb 2017 According to a Chimerix media release, final data from this trial presented at the BMT Tandem Meetings 2017.
- 22 Feb 2017 Results from Cohort A and B (n=158) published in the Chimerix Media Release